the fact they NEVER deny what epgl claimed publicly in several filings at Otcmarket website and especially with a PR threatening of a lawsuit .
"Since 2013 and most notably, since the 2014 Annual report, EPGL has
now successfully progressed several provisional patents pending into
non-provisional and PCT application filings status as projected during
2014 and 2015. This was achieved after extensive project work and
consultation with CooperVision R&D involving onsight materials
delivery and experimentation by CooperVision researchers for proof of
concept. After seeing the successful results of the solutions created and
achieved by EPGL, CooperVision, Inc. moved forward for Intellectual
Property prosecution with EPGl into 2015. These patents continue to be
filed to the present day. As was reported earlier in 2015, EPGL rebuffed
an effort by CooperVision to have a exclusive Option to License EPGL
technology several months earlier than anticipated.
The significance of the technologies which EPGL and CooperVision
have been engaged is that they involve discoveries and breakthroughs in
the integration of microelectronics into modern silicone hydrogel contact
lenses. This is very important as any successfully commercialized
contact lenses containing electronic augmentation or vision
enhancements in the future, will need to be comfortable, safe and mass
manufactured. EPGL believes that some of the technologies it has
developed with CooperVision are leading in the field and have potential
to block other companies within the field from achieving the same
successful integration of electronics into mass manufactured contact
lenses without negotiation of royalties and compensation to EPGL and
CooperVision."
"in December 2014, CooperVision, Inc. asked EPGL to grant the Exclusive Option to license EPGL jointly developed ophthalmic technologies.
EPGL refused to do so, contending that the Development Agreement was
breached and did not allow the granting of the Option for several more months after all joint IP was fully filed. EPGL threatened litigation over the issue. In May 2015, CooperVision, Inc. suggested mediation and EPGL agreed to do so. As announced publicly in a jointly approved January 2016 PR, after several months of negotiations, a settlement was reached whereby, to avoid litigation, the parties would agree that CooperVision, Inc. will retain rights and license to use the joint
technology in their products in exchange for cash payment and EPGL receiving assignment of the IP and 100% ownership control and marketing rights worldwide."
"EPGL believes that CooperVision Inc. has breached a contract Agreement between the two companies in several ways, most notably by demanding exclusive licensing rights nine months earlier than the Agreement called for and for failure to negotiate in good faith per certain Terms of the Agreement. ""
"“CooperVision asked EPGL to solve problems and invent these technologies jointly under Agreement and now claims co-ownership with rights of refusal etc. It’s time to pay your fair share CooperVision, or relinquish the technologies free and clear to EPGL. You are utilizing assets that you have not negotiated properly and paid for under the Contract.” Said Michael Hayes, "
"“They recently lured EPGL into mediation on this issue to avoid a lawsuit and they clearly understand the value of the technology and the coming market because their R&D team valued just one new bionic contact lens application at nearly $5 Billion annual revenues. This is only one and we have several possible applications for the technology. They will not give up their rights to EPGL because they know the potential value of these key technologies over the next several years."
"EPGL is demanding that by June 17, 2015 CooperVision, Inc. relinquish all rights title and interest to their 50% ownership stake in several key patents, as settlement with EPGL, or EPGL will sue The Cooper Companies, Inc. for breach of contract and fraudulent inducement, for $4.35 Billion dollars in fees and punitive damages"
"It goes without saying that certain EPGL technologies related to Autofocus will require royalties from any and all companies who choose to integrate it into their products, including CooperVision, Inc. EPGL will not disclose specific Terms and licensing retained by CooperVision, Inc. under the Settlement Agreement because both parties agreed to maintain confidentiality. But make no mistake; if certain patents pending in Autofocus are granted, ANY COMPANY using will pay royalties for use."
Market Data 
Markets 
